{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:14:05Z","timestamp":1791684845844,"version":"4.3.4"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma (GBM) has remained relatively unresponsive to immunotherapy, with scattered durable responses reported in early CAR T-cell studies, but without clear benefit at the population level. The major challenge for GBM has been its heterogeneous nature with a significantly immunosuppressive microenvironment that is predominantly composed of myeloid cells, inhibiting T-cell infiltration, function, and providing a rapid pathway for adaptive resistance. The focus of this review is to reposition GBM CAR T-cell therapy as a systems-level issue, turning localized CAR T-cell cytotoxicity into sustained control of the disease by engaging endogenous antitumor immunity via cytokine myeloid chemokine networks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We integrated both mechanism- and translation-oriented evidence for how inflammatory mediators derived from CAR T cells (Type I IFNs, IFN-\u03b3, TNF) may license microglia\/tumor-associated macrophages for antigen presentation and chemokine secretion, thus recruiting host effector cells and promoting antigen epitope spreading. To place this work within the context of current engineering trends, the current paper undertook a structured meta-synthesis on registry trials for interventional CAR T therapy for GBM using ClinicalTrials.gov. Using a structured advanced search strategy, we searched 91 registry records, found 44 trials for interventional CAR T therapy, and evaluated 23 active trials commenced after January 2020. Trials were classified based on target antigen choice, multi-antigen OR-gated approaches, conditional AND-gated synNotch logic, as well as safety and controllability measures (inducible off-switches).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The effectiveness of CAR T cells for GBM is not likely to be actualized by targeting alone and needs to incorporate both killing and productive self-reinforcing endogenous immunity via myeloid licensing and chemokine amplification. Current trials are increasingly integrating this paradigm with a focus on more comprehensive antigens, gated CARs, immune-conjugate payloads, and safety designs amenable to the CNS without major toxicity such as ICANS. Future translation will require a focus on implementing endogenous immune activation as a quantified endpoint (including cytokine and chemokine analysis within CSF) and a simultaneous focus on immune set points that maintain cross-priming and memory without unmasking neuroinflammatory toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05497-4","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T03:13:11Z","timestamp":1773371591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Endogenous immune recruitment in glioblastoma CAR T therapy: cytokine, myeloid, and chemokine circuitry"],"prefix":"10.1007","volume":"177","author":[{"given":"Justin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Abikenari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas","family":"Annagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Nageeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Adam","family":"Sjoholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaithish","family":"Velazhahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Medikonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"5497_CR1","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","volume":"26","author":"M Price","year":"2024","unstructured":"Price M, Ballard C, Benedetti J et al (2024) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017\u20132021. Neuro-Oncol 26:vi1\u2013vi85","journal-title":"Neuro-Oncol"},{"key":"5497_CR2","first-page":"4","volume":"24","author":"YK Durga","year":"2026","unstructured":"Durga YK, Pusapati RV (2026) Drug resistance in glioblastoma: Challenges, mechanisms and therapeutic strategies (Review). Mol Clin Oncol 24:4","journal-title":"Mol Clin Oncol"},{"key":"5497_CR3","first-page":"87","volume":"38","author":"X Wang","year":"2019","unstructured":"Wang X, Guo G, Guan H et al (2019) Challenges and potential of PD-1\/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer Res CR 38:87","journal-title":"J Exp Clin Cancer Res CR"},{"key":"5497_CR4","first-page":"5075","volume":"0","author":"MA Abikenari","year":"2024","unstructured":"Abikenari MA, Enayati I, Fountain DM et al (2024) Navigating glioblastoma therapy: A narrative review of emerging immunotherapeutics and small-molecule inhibitors. Microbes Immun 0:5075","journal-title":"Microbes Immun"},{"key":"5497_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/ph19010148","volume":"19","author":"K Dynarowicz","year":"2026","unstructured":"Dynarowicz K, Smolak B, Bartusik-Aebisher D et al (2026) Current Pharmacotherapeutic Strategies in Diffuse Gliomas: Focus on Glioblastoma, IDH-Wildtype, and Emerging Targeted Therapies for IDH-Mutant Tumors. Pharmaceuticals 19:148","journal-title":"Pharmaceuticals"},{"key":"5497_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/glioma.glioma_4_24","volume":"7","author":"M Abikenari","year":"2024","unstructured":"Abikenari M, Schonfeld E, Choi J et al (2024) Revisiting glioblastoma classification through an immunological lens: A narrative review. Glioma 7:3\u20139","journal-title":"Glioma"},{"key":"5497_CR7","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41423-020-0470-3","volume":"17","author":"L Wu","year":"2020","unstructured":"Wu L, Wei Q, Brzostek J et al (2020) Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells. Cell Mol Immunol 17:600\u2013612","journal-title":"Cell Mol Immunol"},{"key":"5497_CR8","doi-asserted-by":"publisher","unstructured":"Ershova A, Goldaeva A, Staliarova A et al Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematology. Front Immunol. 16. Epub ahead of print 14 July 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1592377.","DOI":"10.3389\/fimmu.2025.1592377"},{"key":"5497_CR9","doi-asserted-by":"publisher","first-page":"2210046","DOI":"10.1080\/21645515.2023.2210046","volume":"19","author":"R Awasthi","year":"2023","unstructured":"Awasthi R, Maier HJ, Zhang J et al (2023) Kymriah\u00ae (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy. Hum Vaccines Immunother 19:2210046","journal-title":"Hum Vaccines Immunother"},{"key":"5497_CR10","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.3390\/ijms21113906","volume":"21","author":"A Ahmad","year":"2020","unstructured":"Ahmad A, Uddin S, Steinhoff M, CAR-T Cell Therapies (2020) An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas. Int J Mol Sci 21:3906","journal-title":"Int J Mol Sci"},{"key":"5497_CR11","unstructured":"Gene targets of CAR-T cell therapy for glioblastoma - PMC https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10136592\/. Accessed 21 Jan 2026."},{"key":"5497_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41587-019-0329-2","volume":"38","author":"M MacKay","year":"2020","unstructured":"MacKay M, Afshinnekoo E, Rub J et al (2020) The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat Biotechnol 38:233\u2013244","journal-title":"Nat Biotechnol"},{"key":"5497_CR13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute G, Prinzing BL, Yi Z et al (2017) Transgenic Expression of IL15 Improves Antiglioma Activity of IL13R\u03b12-CAR T Cells but Results in Antigen Loss Variants. Cancer Immunol Res 5:571\u2013581","journal-title":"Cancer Immunol Res"},{"key":"5497_CR14","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","volume":"28","author":"JH Sampson","year":"2010","unstructured":"Sampson JH, Heimberger AB, Archer GE et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 28:4722\u20134729","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5497_CR15","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A et al (2017) A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 9:eaaa0984","journal-title":"Sci Transl Med"},{"key":"5497_CR16","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R et al (2016) Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med 375:2561\u20132569","journal-title":"N Engl J Med"},{"key":"5497_CR17","doi-asserted-by":"publisher","first-page":"e35935","DOI":"10.1002\/cncr.35935","volume":"131","author":"R Medikonda","year":"2025","unstructured":"Medikonda R, Abikenari MA, Schonfeld E et al (2025) Top advances of the year: The status of chimeric antigen receptor T cells in neuro-oncology. Cancer 131:e35935","journal-title":"Cancer"},{"key":"5497_CR18","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1186\/s12885-019-5861-4","volume":"19","author":"E Skaga","year":"2019","unstructured":"Skaga E, Kulesskiy E, Fayzullin A et al (2019) Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-na\u00efve glioblastoma. BMC Cancer 19:628","journal-title":"BMC Cancer"},{"key":"5497_CR19","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1073\/pnas.1219747110","volume":"110","author":"A Sottoriva","year":"2013","unstructured":"Sottoriva A, Spiteri I, Piccirillo SGM et al (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci 110:4009\u20134014","journal-title":"Proc Natl Acad Sci"},{"key":"5497_CR20","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel C, Laffy J, Filbin MG et al (2019) An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell 178:835\u2013849e21","journal-title":"Cell"},{"key":"5497_CR21","doi-asserted-by":"publisher","first-page":"e85841","DOI":"10.1172\/jci.insight.85841","volume":"1","author":"K Gabrusiewicz","year":"2016","unstructured":"Gabrusiewicz K, Rodriguez B, Wei J et al (2016) Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight 1:e85841","journal-title":"JCI Insight"},{"key":"5497_CR22","doi-asserted-by":"publisher","first-page":"CNS21","DOI":"10.2217\/cns-2017-0037","volume":"7","author":"E Orrego","year":"2018","unstructured":"Orrego E, Castaneda CA, Castillo M et al (2018) Distribution of tumor-infiltrating immune cells in glioblastoma. CNS Oncol 7:CNS21","journal-title":"CNS Oncol"},{"key":"5497_CR23","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/S1474-4422(08)70164-9","volume":"7","author":"AIR Maas","year":"2008","unstructured":"Maas AIR, Stocchetti N, Bullock R (2008) Moderate and severe traumatic brain injury in adults. Lancet Neurol 7:728\u2013741","journal-title":"Lancet Neurol"},{"key":"5497_CR24","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3390\/cancers17111881","volume":"17","author":"R Medikonda","year":"2025","unstructured":"Medikonda R, Abikenari M, Schonfeld E et al (2025) The Metabolic Orchestration of Immune Evasion in Glioblastoma: From Molecular Perspectives to Therapeutic Vulnerabilities. Cancers 17:1881","journal-title":"Cancers"},{"key":"5497_CR25","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1158\/1078-0432.CCR-17-2617","volume":"24","author":"M Mohme","year":"2018","unstructured":"Mohme M, Schliffke S, Maire CL et al (2018) Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes. Clin Cancer Res Off J Am Assoc Cancer Res 24:4187\u20134200","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"5497_CR26","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","volume":"24","author":"K Woroniecka","year":"2018","unstructured":"Woroniecka K, Chongsathidkiet P, Rhodin K et al (2018) T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. Clin Cancer Res Off J Am Assoc Cancer Res 24:4175\u20134186","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"5497_CR27","doi-asserted-by":"crossref","unstructured":"Hu B, Ren J, Luo Y et al (2017) Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Reports. 20(13):3025\u20133033. Accessed 21 Jan 2026.","DOI":"10.1016\/j.celrep.2017.09.002"},{"key":"5497_CR28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1042\/BST20150291","volume":"44","author":"OO Yeku","year":"2016","unstructured":"Yeku OO, Brentjens RJ (2016) Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans 44:412\u2013418","journal-title":"Biochem Soc Trans"},{"key":"5497_CR29","doi-asserted-by":"publisher","first-page":"108734","DOI":"10.1016\/j.biopha.2019.108734","volume":"113","author":"M Chen","year":"2019","unstructured":"Chen M, Sun R, Shi B et al (2019) Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL\/6 mice. Biomed Pharmacother 113:108734","journal-title":"Biomed Pharmacother"},{"key":"5497_CR30","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1158\/1078-0432.CCR-13-0709","volume":"20","author":"JH Sampson","year":"2014","unstructured":"Sampson JH, Choi BD, Sanchez-Perez L et al (2014) EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res Off J Am Assoc Cancer Res 20:972\u2013984","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"5497_CR31","doi-asserted-by":"publisher","first-page":"100826","DOI":"10.1016\/j.currproblcancer.2021.100826","volume":"46","author":"N Denlinger","year":"2022","unstructured":"Denlinger N, Bond D, Jaglowski S (2022) CAR T-cell therapy for B-cell lymphoma. Curr Probl Cancer 46:100826","journal-title":"Curr Probl Cancer"},{"key":"5497_CR32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 20:359\u2013371","journal-title":"Nat Rev Clin Oncol"},{"key":"5497_CR33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1182\/blood.2020009515","volume":"138","author":"K Wudhikarn","year":"2021","unstructured":"Wudhikarn K, Flynn JR, Rivi\u00e8re I et al (2021) Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood 138:531\u2013543","journal-title":"Blood"},{"key":"5497_CR34","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507\u20131517","journal-title":"N Engl J Med"},{"key":"5497_CR35","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M et al (2018) Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med 378:449\u2013459","journal-title":"N Engl J Med"},{"key":"5497_CR36","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang W-T, Frey NV et al (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7:303ra139\u2013303ra139","journal-title":"Sci Transl Med"},{"key":"5497_CR37","unstructured":"Vieira dos Santos J, Melnekoff DT, Aleman A et al (2025) Long-term remission after cilta-cel in multiple myeloma is linked to diverse t cells and low myeloid suppression. Blood Adv. 2025018078."},{"key":"5497_CR38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","volume":"11","author":"R Upadhyay","year":"2021","unstructured":"Upadhyay R, Boiarsky JA, Pantsulaia G et al (2021) A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. Cancer Discov 11:599\u2013613","journal-title":"Cancer Discov"},{"key":"5497_CR39","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma L, Hostetler A, Morgan DM et al (2023) Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell 186:3148\u20133165e20","journal-title":"Cell"},{"key":"5497_CR40","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12967-025-06543-x","volume":"23","author":"N An","year":"2025","unstructured":"An N, Li J, Luo P et al (2025) Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed\/refractory multiple myeloma. J Transl Med 23:552","journal-title":"J Transl Med"},{"key":"5497_CR41","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-13-0985","volume":"4","author":"I Melero","year":"2014","unstructured":"Melero I, Rouzaut A, Motz GT et al (2014) T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy. Cancer Discov 4:522\u2013526","journal-title":"Cancer Discov"},{"key":"5497_CR42","doi-asserted-by":"publisher","first-page":"e58688","DOI":"10.7554\/eLife.58688","volume":"10","author":"A Nicolas-Boluda","year":"2021","unstructured":"Nicolas-Boluda A, Vaquero J, Vimeux L et al (2021) Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. eLife 10:e58688","journal-title":"eLife"},{"key":"5497_CR43","doi-asserted-by":"publisher","first-page":"751311","DOI":"10.3389\/fonc.2021.751311","volume":"11","author":"VM Perez","year":"2021","unstructured":"Perez VM, Kearney JF, Yeh JJ (2021) The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies. Front Oncol 11:751311","journal-title":"Front Oncol"},{"key":"5497_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-025-01744-9","volume":"18","author":"M-C Vo","year":"2025","unstructured":"Vo M-C, Tran V-D-H, Nguyen V-T et al (2025) Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies? J Hematol OncolJ Hematol Oncol 18:91","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"5497_CR45","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Todd L, Huang L et al (2023) Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat Commun 14:5110","journal-title":"Nat Commun"},{"key":"5497_CR46","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, Savoldo B, Hoyos V et al (2015) Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 21:524\u2013529","journal-title":"Nat Med"},{"key":"5497_CR47","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ymthe.2019.10.010","volume":"28","author":"C Deng","year":"2020","unstructured":"Deng C, Zhao J, Zhou S et al (2020) The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors. Mol Ther J Am Soc Gene Ther 28:75\u201388","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"5497_CR48","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.20160801","volume":"214","author":"VR Juneja","year":"2017","unstructured":"Juneja VR, McGuire KA, Manguso RT et al (2017) PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med 214:895\u2013904","journal-title":"J Exp Med"},{"key":"5497_CR49","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793\u2013800","journal-title":"Nat Med"},{"key":"5497_CR50","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/2326-6066.CIR-16-0391","volume":"5","author":"T Noguchi","year":"2017","unstructured":"Noguchi T, Ward JP, Gubin MM et al (2017) Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Cancer Immunol Res 5:106\u2013117","journal-title":"Cancer Immunol Res"},{"key":"5497_CR51","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","volume":"125","author":"S Ninomiya","year":"2015","unstructured":"Ninomiya S, Narala N, Huye L et al (2015) Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125:3905\u20133916","journal-title":"Blood"},{"key":"5497_CR52","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","volume":"11","author":"LF Campesato","year":"2020","unstructured":"Campesato LF, Budhu S, Tchaicha J et al (2020) Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat Commun 11:4011","journal-title":"Nat Commun"},{"key":"5497_CR53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00262-024-03925-w","volume":"74","author":"L Guangzhao","year":"2025","unstructured":"Guangzhao L, Xin W, Miaoqing W et al (2025) IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization. Cancer Immunol Immunother CII 74:71","journal-title":"Cancer Immunol Immunother CII"},{"key":"5497_CR54","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF, Palomo-Ponce S, Stork D et al (2018) TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554:538\u2013543","journal-title":"Nature"},{"key":"5497_CR55","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D et al (2018) TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544\u2013548","journal-title":"Nature"},{"key":"5497_CR56","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942\u2013949","journal-title":"Nat Med"},{"key":"5497_CR57","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas AR, Tanyi JL, O\u2019Hara MH et al (2019) Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Mol Ther J Am Soc Gene Ther 27:1919\u20131929","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"5497_CR58","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41540-024-00435-4","volume":"10","author":"E Kara","year":"2024","unstructured":"Kara E, Jackson TL, Jones C et al (2024) Mathematical modeling insights into improving CAR T cell therapy for solid tumors with bystander effects. Npj Syst Biol Appl 10:105","journal-title":"Npj Syst Biol Appl"},{"key":"5497_CR59","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","volume":"155","author":"GL Beatty","year":"2018","unstructured":"Beatty GL, O\u2019Hara MH, Lacey SF et al (2018) Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology 155:29\u201332","journal-title":"Gastroenterology"},{"key":"5497_CR60","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi MP, Yeku O, Li X et al (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130\u20132141","journal-title":"Cell Rep"},{"key":"5497_CR61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2013","unstructured":"Chmielewski M, Hombach AA, Abken H (2013) Of <\u2009scp>CAR\u2009s and <\u2009scp>TRUCK\u2009s: chimeric antigen receptor (<\u2009scp>CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 257:83\u201390","journal-title":"Immunol Rev"},{"key":"5497_CR62","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J et al (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 126:3130\u20133144","journal-title":"J Clin Invest"},{"key":"5497_CR63","doi-asserted-by":"publisher","unstructured":"Jorgovanovic D, Song M, Wang L et al Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark Res; 8. Epub ahead of print September 2020. https:\/\/doi.org\/10.1186\/s40364-020-00228-x","DOI":"10.1186\/s40364-020-00228-x"},{"key":"5497_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-025-05170-2","volume":"175","author":"M Abikenari","year":"2025","unstructured":"Abikenari M, Liu J, Ha JH et al (2025) Emerging trends in cell-based therapies: contemporary advances and ethical considerations in translational neurosurgical oncology. J Neurooncol 175:1\u201320","journal-title":"J Neurooncol"},{"key":"5497_CR65","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503\u2013511","journal-title":"Nature"},{"key":"5497_CR66","doi-asserted-by":"publisher","unstructured":"Abikenari M, Sjoholm MA, Liu J et al Molecular and biophysical remodeling of the blood\u2013brain barrier in glioblastoma: mechanistic drivers of tumor\u2013neurovascular crosstalk. Front Phys; 13. Epub ahead of print 18 December 2025. https:\/\/doi.org\/10.3389\/fphy.2025.1723329","DOI":"10.3389\/fphy.2025.1723329"},{"key":"5497_CR67","doi-asserted-by":"publisher","first-page":"C52","DOI":"10.1152\/ajpcell.00278.2017","volume":"315","author":"H-J Zhou","year":"2018","unstructured":"Zhou H-J, Wang L-Q, Wang D-B et al (2018) Long noncoding RNA MALAT1 contributes to inflammatory response of microglia following spinal cord injury via the modulation of a miR-199b\/IKK\u03b2\/NF-\u03baB signaling pathway. Am J Physiol-Cell Physiol 315:C52\u2013C61","journal-title":"Am J Physiol-Cell Physiol"},{"key":"5497_CR68","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","volume":"120","author":"N Tokarew","year":"2018","unstructured":"Tokarew N, Ogonek J, Endres S et al (2018) Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer 120:26\u201337","journal-title":"Br J Cancer"},{"key":"5497_CR69","doi-asserted-by":"publisher","unstructured":"Gardam B, Gargett T, Brown MP et al Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma. Front Immunol; 14. Epub ahead of print 20 October 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1261257","DOI":"10.3389\/fimmu.2023.1261257"},{"key":"5497_CR70","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski M, Kopecky C, Hombach AA et al (2011) IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 71:5697\u20135706","journal-title":"Cancer Res"},{"key":"5497_CR71","doi-asserted-by":"publisher","unstructured":"Agliardi G, Liuzzi AR, Hotblack A et al Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun; 12. Epub ahead of print January 2021. https:\/\/doi.org\/10.1038\/s41467-020-20599-x","DOI":"10.1038\/s41467-020-20599-x"},{"key":"5497_CR72","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski M, Abken H, CAR T, Cells Releasing (2017) IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors. Cell Rep 21:3205\u20133219","journal-title":"Cell Rep"},{"key":"5497_CR73","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.immuni.2024.02.001","volume":"57","author":"AN Shouse","year":"2024","unstructured":"Shouse AN, LaPorte KM, Malek TR (2024) Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer. Immunity 57:414\u2013428","journal-title":"Immunity"},{"key":"5497_CR74","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","volume":"42","author":"SL Goff","year":"2019","unstructured":"Goff SL, Morgan RA, Yang JC et al (2019) Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor\u2013transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. J Immunother 42:126","journal-title":"J Immunother"},{"key":"5497_CR75","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","volume":"24","author":"CE Brown","year":"2022","unstructured":"Brown CE, Rodriguez A, Palmer J et al (2022) Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma. Neuro-Oncol 24:1318\u20131330","journal-title":"Neuro-Oncol"},{"key":"5497_CR76","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/ijms22052719","volume":"22","author":"D Jang","year":"2021","unstructured":"Jang D, Lee A-H, Shin H-Y et al (2021) The Role of Tumor Necrosis Factor Alpha (TNF-\u03b1) in Autoimmune Disease and Current TNF-\u03b1 Inhibitors in Therapeutics. Int J Mol Sci 22:2719","journal-title":"Int J Mol Sci"},{"key":"5497_CR77","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ymthe.2018.02.001","volume":"26","author":"KC Pituch","year":"2018","unstructured":"Pituch KC, Miska J, Krenciute G et al (2018) Adoptive Transfer of IL13R\u03b12-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma. Mol Ther 26:986\u2013995","journal-title":"Mol Ther"},{"key":"5497_CR78","doi-asserted-by":"crossref","unstructured":"Lee KM, Achuthan AA, Hamilton JA. GM-CSF: A Promising Target in Inflammation and Autoimmunity ImmunoTargets Ther 2020; Volume 9: 225\u2013240","DOI":"10.2147\/ITT.S262566"},{"key":"5497_CR79","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/sj.cr.7310017","volume":"16","author":"Y Shi","year":"2006","unstructured":"Shi Y, Liu CH, Roberts AI et al (2006) Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don\u2019t know. Cell Res 16:126\u2013133","journal-title":"Cell Res"},{"key":"5497_CR80","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.4049\/jimmunol.1103019","volume":"188","author":"P Spear","year":"2012","unstructured":"Spear P, Barber A, Rynda-Apple A et al (2012) Chimeric Antigen Receptor T Cells Shape Myeloid Cell Function within the Tumor Microenvironment through IFN-\u03b3 and GM-CSF. J Immunol 188:6389\u20136398","journal-title":"J Immunol"},{"key":"5497_CR81","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi L, Guilbaud E, Schmidt D et al (2024) Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov 23:445\u2013460","journal-title":"Nat Rev Drug Discov"},{"key":"5497_CR82","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1158\/1078-0432.CCR-20-0305","volume":"26","author":"P Brossart","year":"2020","unstructured":"Brossart P (2020) The Role of Antigen Spreading in the Efficacy of Immunotherapies. Clin Cancer Res 26:4442\u20134447","journal-title":"Clin Cancer Res"},{"key":"5497_CR83","unstructured":"Modulating the glioma (2025) microenvironment with laser interstitial thermal therapy: mechanisms and therapeutic implications. J Neuro Oncol. https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05305-5. Accessed 30 Nov 2025."},{"key":"5497_CR84","doi-asserted-by":"publisher","unstructured":"Chen J, Yang Y, Luan S et al Tertiary lymphoid structures in gliomas: impact on tumour immunity and progression. J Transl Med; 23. Epub ahead of print May 2025. https:\/\/doi.org\/10.1186\/s12967-025-06510-6.","DOI":"10.1186\/s12967-025-06510-6"},{"key":"5497_CR85","doi-asserted-by":"publisher","unstructured":"van de Walle T, Vaccaro A, Ramachandran M, et al Tertiary lymphoid structures in the central nervous system: implications for glioblastoma. Front Immunol. 12. Epub ahead of print September 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.724739.","DOI":"10.3389\/fimmu.2021.724739"},{"key":"5497_CR86","doi-asserted-by":"publisher","first-page":"578146","DOI":"10.1016\/j.jneuroim.2023.578146","volume":"381","author":"M Sabahi","year":"2023","unstructured":"Sabahi M, Salehipour A, Bazl MSY et al (2023) Local immunotherapy of glioblastoma: A comprehensive review of the concept. J Neuroimmunol 381:578146","journal-title":"J Neuroimmunol"},{"key":"5497_CR87","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown CE, Hibbard JC, Alizadeh D et al (2024) Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med 30:1001\u20131012","journal-title":"Nat Med"},{"key":"5497_CR88","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/2159-8290.CD-20-1661","volume":"11","author":"D Alizadeh","year":"2021","unstructured":"Alizadeh D, Wong RA, Gholamin S et al (2021) IFN\u03b3 Is Critical for CAR T Cell\u2013Mediated Myeloid Activation and Induction of Endogenous Immunity. Cancer Discov 11:2248\u20132265","journal-title":"Cancer Discov"},{"key":"5497_CR89","doi-asserted-by":"publisher","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A et al A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 9. Epub ahead of print 19 July 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"5497_CR90","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/neuonc\/noy032","volume":"20","author":"SJ Bagley","year":"2018","unstructured":"Bagley SJ, Desai AS, Linette GP et al (2018) CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro-Oncol 20:1429\u20131438","journal-title":"Neuro-Oncol"},{"key":"5497_CR91","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","volume":"11","author":"EL Siegler","year":"2020","unstructured":"Siegler EL, Kenderian SS (2020) Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Front Immunol 11:1973","journal-title":"Front Immunol"},{"key":"5497_CR92","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M et al (2018) Cytokine release syndrome. J Immunother Cancer 6:56","journal-title":"J Immunother Cancer"},{"key":"5497_CR93","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet Lond Engl 385:517\u2013528","journal-title":"Lancet Lond Engl"},{"key":"5497_CR94","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C et al (2017) Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129:3322\u20133331","journal-title":"Blood"},{"key":"5497_CR95","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/cpt.3751","volume":"118","author":"C Jamois","year":"2025","unstructured":"Jamois C, Turner DC, Gibiansky L et al (2025) Tocilizumab Dosing for Management of T Cell-Engaging Bispecific Antibody-Related CRS in Patients With R\/R B-Cell NHL. Clin Pharmacol Ther 118:917\u2013927","journal-title":"Clin Pharmacol Ther"},{"key":"5497_CR96","doi-asserted-by":"publisher","first-page":"694941","DOI":"10.3389\/fonc.2021.694941","volume":"11","author":"Q Lin","year":"2021","unstructured":"Lin Q, Ba T, Ho J et al (2021) First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose. Front Oncol 11:694941","journal-title":"Front Oncol"},{"key":"5497_CR97","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje M, Mahdi J, Majzner R et al (2025) Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature 637:708\u2013715","journal-title":"Nature"},{"key":"5497_CR98","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s11060-025-05347-9","volume":"176","author":"J Liu","year":"2025","unstructured":"Liu J, Ha JH, Abikenari M et al (2025) Adaptive immunotherapeutic paradigms in diffuse midline glioma: integrating epigenetic reprogramming, neuron\u2013glioma interactions, and tumor microenvironment modulation. J Neurooncol 176:144","journal-title":"J Neurooncol"},{"key":"5497_CR99","doi-asserted-by":"publisher","first-page":"879608","DOI":"10.3389\/fimmu.2022.879608","volume":"13","author":"RC Sterner","year":"2022","unstructured":"Sterner RC, Sterner RM (2022) Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Front Immunol 13:879608","journal-title":"Front Immunol"},{"key":"5497_CR100","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL et al (2017) Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther J Am Soc Gene Ther 25:285\u2013295","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"5497_CR101","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-3-030-94353-0_27","volume-title":"The EBMT\/EHA CAR-T Cell Handbook","author":"JH Rees","year":"2022","unstructured":"Rees JH (2022) Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). In: Kr\u00f6ger N, Gribben J, Chabannon C et al (eds) The EBMT\/EHA CAR-T Cell Handbook. Springer, Cham (CH), pp 141\u2013145"},{"key":"5497_CR102","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi J, Dietrich J, Straathof K et al (2023) Tumor inflammation-associated neurotoxicity. Nat Med 29:803\u2013810","journal-title":"Nat Med"},{"key":"5497_CR103","doi-asserted-by":"publisher","first-page":"e163446","DOI":"10.1172\/JCI163446","volume":"133","author":"F Khan","year":"2024","unstructured":"Khan F, Pang L, Dunterman M et al (2024) Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. J Clin Invest 133:e163446","journal-title":"J Clin Invest"},{"key":"5497_CR104","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy TF, Mochizuki AY, Orpilla JR et al (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25:477\u2013486","journal-title":"Nat Med"},{"key":"5497_CR105","doi-asserted-by":"publisher","first-page":"10757","DOI":"10.1038\/s41467-024-54326-7","volume":"15","author":"JR McFaline-Figueroa","year":"2024","unstructured":"McFaline-Figueroa JR, Sun L, Youssef GC et al (2024) Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort. Nat Commun 15:10757","journal-title":"Nat Commun"},{"key":"5497_CR106","unstructured":"Low-dose radiation (2026) by radiopharmaceutical therapy enhances GD2 TRAC-CAR T cell efficacy in localized neuroblastoma. Sci Adv. https:\/\/www.science.org\/doi\/10.1126\/sciadv.adu4417?utm_source=chatgpt.com. Accessed 2 Jan 2026."},{"key":"5497_CR107","doi-asserted-by":"publisher","first-page":"e2111003119","DOI":"10.1073\/pnas.2111003119","volume":"119","author":"G Berger","year":"2022","unstructured":"Berger G, Knelson EH, Jimenez-Macias JL et al (2022) STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models. Proc Natl Acad Sci U S A 119:e2111003119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5497_CR108","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","volume":"31","author":"SJ Bagley","year":"2025","unstructured":"Bagley SJ, Desai AS, Fraietta JA et al (2025) Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial. Nat Med 31:2778\u20132787","journal-title":"Nat Med"},{"key":"5497_CR109","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi BD, Yu X, Castano AP et al (2019) CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol 37:1049\u20131058","journal-title":"Nat Biotechnol"},{"key":"5497_CR110","doi-asserted-by":"publisher","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","volume":"13","author":"JH Choe","year":"2021","unstructured":"Choe JH, Watchmaker PB, Simic MS et al (2021) SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med 13:eabe7378","journal-title":"Sci Transl Med"},{"key":"5497_CR111","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ebiom.2019.08.030","volume":"47","author":"D Nehama","year":"2019","unstructured":"Nehama D, Di Ianni N, Musio S et al (2019) B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. EBioMedicine 47:33\u201343","journal-title":"EBioMedicine"},{"key":"5497_CR112","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel C, Laffy J, Filbin MG et al (2019) An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell 178:835\u2013849e21","journal-title":"Cell"},{"key":"5497_CR113","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/neuonc\/nou045","volume":"16","author":"B Thaci","year":"2014","unstructured":"Thaci B, Brown CE, Binello E et al (2014) Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro-Oncol 16:1304\u20131312","journal-title":"Neuro-Oncol"},{"key":"5497_CR114","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/neuonc\/nox116","volume":"20","author":"L Jin","year":"2018","unstructured":"Jin L, Ge H, Long Y et al (2018) CD70, a novel target of CAR T-cell therapy for gliomas. Neuro-Oncol 20:55\u201365","journal-title":"Neuro-Oncol"},{"key":"5497_CR115","unstructured":"Luo X, Wang X, Eweje F et al (2025) Ensemble learning of foundation models for precision oncology. arXiv org, https:\/\/arxiv.org\/abs\/2508.16085v1. Accessed 8 Jan 2026."},{"key":"5497_CR116","doi-asserted-by":"publisher","unstructured":"Abikenari M, Jain B, Xu R et al Bridging imaging and molecular biomarkers in trigeminal neuralgia: toward precision diagnosis and prognostication in neuropathic pain. Med Res Arch. 13. Epub ahead of print 30 May 2025. https:\/\/doi.org\/10.18103\/mra.v13i5.6605","DOI":"10.18103\/mra.v13i5.6605"},{"key":"5497_CR117","doi-asserted-by":"publisher","first-page":"109137","DOI":"10.1016\/j.compbiomed.2024.109137","volume":"182","author":"A Boretti","year":"2024","unstructured":"Boretti A (2024) The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy. Comput Biol Med 182:109137","journal-title":"Comput Biol Med"},{"key":"5497_CR118","unstructured":"Reframing clinical AI evaluation in the era of generative models (2026) toward multidimensional, stakeholder-informed, and safety-centric frameworks for real-world health care deployment. Prem Sci. https:\/\/premierscience.com\/pjs-25-1011\/. Accessed 22\u00a0Jan 2026."},{"key":"5497_CR119","unstructured":"Full article (2019) Artificial intelligence and immunotherapy. 1623670 https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1744666X. Accessed 22 Jan 2026."}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05497-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05497-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05497-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:04:33Z","timestamp":1776074673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05497-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["5497"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05497-4","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal and human studies Experimental approval board"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosure"}},{"value":"No pertinent conflicts of interest relevant to this manuscript.\u202f\u202f\u202f\u202f Michael Lim: (Funding from Arbor Pharmaceuticals, Accuray, BMS, Novartis; Consultant: BMS, Merck, SQZ Biotechnologies, Tocagen, VBI; Patents: Combining Focused Radiation and Immunotherapy, Combining Local Chemotherapy and Immunotherapy; Shareholder: Egret Therapeutics).\u202f\u202f\u202fGordon Li: Consultant for Medtronic, and received funding from Novocure and Targtex.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}